Of further relevance, the incidence of cancer in individuals carrying a fully inactivating PMS2 variant is lower than that in individuals carrying a fully inactivating MSH2 or MLH1 variant, which results from the partial genetic redundancy of PMS2 with minor MMR proteins (notably MLH3 or PMS1). This evidence concerns the gene MLH3 and cancer.